PE20121396A1 - Composicion farmaceutica que comprende bromuro de glicopirronio y formoterol - Google Patents
Composicion farmaceutica que comprende bromuro de glicopirronio y formoterolInfo
- Publication number
- PE20121396A1 PE20121396A1 PE2012000865A PE2012000865A PE20121396A1 PE 20121396 A1 PE20121396 A1 PE 20121396A1 PE 2012000865 A PE2012000865 A PE 2012000865A PE 2012000865 A PE2012000865 A PE 2012000865A PE 20121396 A1 PE20121396 A1 PE 20121396A1
- Authority
- PE
- Peru
- Prior art keywords
- formoterol
- bromide
- pharmaceutical composition
- composition including
- glycopyronium
- Prior art date
Links
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 title abstract 4
- 229960002848 formoterol Drugs 0.000 title abstract 3
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000005828 hydrofluoroalkanes Chemical class 0.000 abstract 2
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 abstract 1
- LFQSCWFLJHTTHZ-HQMMCQRPSA-N Ethanol-14C Chemical compound C[14CH2]O LFQSCWFLJHTTHZ-HQMMCQRPSA-N 0.000 abstract 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 abstract 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229950000210 beclometasone dipropionate Drugs 0.000 abstract 1
- 229940124748 beta 2 agonist Drugs 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 229960001334 corticosteroids Drugs 0.000 abstract 1
- 239000006184 cosolvent Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000003149 muscarinic antagonist Substances 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/124—Aerosols; Foams characterised by the propellant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
- B65B3/04—Methods of, or means for, filling the material into the containers or receptacles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B31/00—Packaging articles or materials under special atmospheric or gaseous conditions; Adding propellants to aerosol containers
- B65B31/003—Adding propellants in fluid form to aerosol containers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B7/00—Closing containers or receptacles after filling
- B65B7/16—Closing semi-rigid or rigid containers or receptacles not deformed by, or not taking-up shape of, contents, e.g. boxes or cartons
- B65B7/28—Closing semi-rigid or rigid containers or receptacles not deformed by, or not taking-up shape of, contents, e.g. boxes or cartons by applying separate preformed closures, e.g. lids, covers
- B65B7/2842—Securing closures on containers
- B65B7/285—Securing closures on containers by deformation of the closure
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Mechanical Engineering (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- External Artificial Organs (AREA)
Abstract
REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE BROMURO DE GLICOPIRRONIO Y FORMOTEROL O UNA SAL DEL MISMO, DISUELTOS EN UN PROPELENTE DE HIDROFLUOROALCANO (HFA) Y UN COSOLVENTE TAL COMO ETANOL, DONDE EL BROMURO DE GLICOPIRRONIO SE ENCUENTRA EN UNA CONCENTRACION DE ENTRE 0,005% Y 0,14% (P/P) Y EL FORMOTEROL EN UNA CONCENTRACION DE ENTRE 0,005% Y 0,07% (P/P). TAMBIEN COMPRENDE UNO O MAS INGREDIENTES FARMACEUTICAMENTE ACTIVOS SELECCIONADOS DE AGONISTAS BETA-2, CORTICOESTEROIDES TALES COMO EL DIPROPIONATO DE BECLOMETASONA, AGENTES ANTIMUSCARINICOS E INHIBIDORES DE FOSFODIESTERASA (IV). DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE TRASTORNOS RESPIRATORIOS, INCLUYENDO EPOC
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09180671 | 2009-12-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20121396A1 true PE20121396A1 (es) | 2012-10-24 |
Family
ID=42107420
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016000787A PE20160853A1 (es) | 2009-12-23 | 2010-12-22 | Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc) |
| PE2012000865A PE20121396A1 (es) | 2009-12-23 | 2010-12-22 | Composicion farmaceutica que comprende bromuro de glicopirronio y formoterol |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016000787A PE20160853A1 (es) | 2009-12-23 | 2010-12-22 | Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc) |
Country Status (41)
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20121467A1 (es) * | 2009-12-23 | 2012-11-07 | Chiesi Farma Spa | Formulacion de aerosol para la enfermedad pulmonar obstructiva cronica |
| JP5914354B2 (ja) * | 2009-12-23 | 2016-05-11 | シエシー ファルマセウティチィ ソシエタ ペル アチオニ | Ｃｏｐｄ用併用療法 |
| ES2468835T3 (es) * | 2009-12-23 | 2014-06-17 | Chiesi Farmaceutici S.P.A. | Terapia combinada para EPOC |
| EP2749284A3 (en) * | 2011-02-17 | 2014-08-20 | Cipla Limited | Combination of glycopyrronium and carmoterol |
| HUE042556T2 (hu) * | 2011-10-11 | 2019-07-29 | Chiesi Farm Spa | Zsírsavval bevont béta-agonista kristályos mikrorészecskéi |
| MX2015003731A (es) * | 2012-10-23 | 2015-06-15 | Cipla Ltd | Composicion farmaceutica. |
| SG11201600110RA (en) | 2013-07-11 | 2016-02-26 | Chiesi Farma Spa | Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation |
| EA033228B1 (ru) * | 2013-12-30 | 2019-09-30 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Находящаяся под давлением стабильная аэрозольная композиция комбинации гликопиррония бромида и формотерола в форме раствора |
| HUE039513T2 (hu) * | 2013-12-30 | 2019-01-28 | Chiesi Farm Spa | Glikopirrónium-bromid és formoterol kombinációját tartalmazó nyomás alatti stabil aeroszol oldatkészítmény |
| US11039620B2 (en) | 2014-02-19 | 2021-06-22 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
| US9622483B2 (en) | 2014-02-19 | 2017-04-18 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
| US11039621B2 (en) | 2014-02-19 | 2021-06-22 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
| US9554992B2 (en) * | 2014-06-09 | 2017-01-31 | Chiesi Farmaceutici S.P.A. | Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic |
| GB201416909D0 (en) * | 2014-09-25 | 2014-11-12 | Prosonix Ltd | Method of forming concentrated solution |
| WO2016170518A1 (en) | 2015-04-24 | 2016-10-27 | Glenmark Specialty S.A. | Pharmaceutical compositions comprising arformoterol and glycopyrronium |
| EA037716B1 (ru) * | 2015-11-16 | 2021-05-13 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Способ получения сухой порошковой композиции, содержащей антихолинергическое средство, кортикостероид и бета-адренергическое средство, порошковая композиция, ингалятор, применение сухой порошковой композиции для профилактики и/или лечения воспалительного и/или обструктивного заболевания дыхательных путей |
| GB2545025A (en) * | 2015-12-04 | 2017-06-07 | Mexichem Fluor Sa De Cv | Pharmaceutical composition |
| WO2017167737A1 (en) | 2016-03-31 | 2017-10-05 | Chiesi Farmaceutici S.P.A. | Aerosol inhalation device |
| US10098837B2 (en) | 2016-07-28 | 2018-10-16 | Chiesi Farmaceutici S.P.A. | Combination therapy for COPD |
| EP3915555B1 (en) | 2016-09-19 | 2023-06-28 | Mexichem Fluor S.A. de C.V. | Pharmaceutical composition comprising glycopyrrolate |
| EP3515439B1 (en) * | 2016-09-19 | 2021-12-15 | Mexichem Fluor S.A. de C.V. | Pharmaceutical composition comprising tiotropium bromide |
| MX2019003099A (es) | 2016-09-19 | 2019-06-10 | Mexichem Fluor Sa De Cv | Composicion farmaceutica. |
| ES2891346T3 (es) | 2017-05-11 | 2022-01-27 | Chiesi Farm Spa | Un proceso para preparar una formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un beta-adrenérgico |
| ES2882153T3 (es) | 2017-05-11 | 2021-12-01 | Chiesi Farm Spa | Un proceso para preparar una formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un betaadrenérgico |
| CA3152578A1 (en) * | 2019-12-02 | 2021-06-10 | Enrico Zambelli | Stainles steel can for pressurised metered dose inhalers |
| MX2023001201A (es) | 2020-07-31 | 2023-05-03 | Chemo Res S L | Terapia combinada para la administracion por inhalacion. |
| CN116419749A (zh) | 2020-10-09 | 2023-07-11 | 奇斯药制品公司 | 用于加压定量吸入器的药物制剂 |
| WO2023227782A1 (en) | 2022-05-27 | 2023-11-30 | Chiesi Farmaceutici S.P.A. | A pharmaceutical formulation for pressurised metered dose inhaler |
| WO2023227783A1 (en) | 2022-05-27 | 2023-11-30 | Chiesi Farmaceutici S.P.A. | A pharmaceutical formulation for pressurised metered dose inhaler |
| WO2023227781A1 (en) | 2022-05-27 | 2023-11-30 | Chiesi Farmaceutici S.P.A. | A pharmaceutical formulation for pressurised metered dose inhaler |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2956062A (en) | 1959-02-26 | 1960-10-11 | Robins Co Inc A H | Esters of amino alcohols |
| NZ259192A (en) | 1992-12-09 | 1997-05-26 | Boehringer Ingelheim Pharma | Aerosol medicament comprising water-sensitive or solvent-sensitive active agent, hfc propellant stabilised by addition of (in)organic acid |
| ATE283033T1 (de) * | 1998-07-24 | 2004-12-15 | Jago Res Ag | Medizinische aerosolformulierungen |
| PT1102579E (pt) | 1998-08-04 | 2003-07-31 | Jago Res Ag | Formulacoes de aerossol medicinais |
| US20060171899A1 (en) * | 1998-12-10 | 2006-08-03 | Akwete Adjei | Water-stabilized aerosol formulation system and method of making |
| IT1317720B1 (it) | 2000-01-07 | 2003-07-15 | Chiesi Farma Spa | Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani. |
| GB0008660D0 (en) | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
| UA73986C2 (uk) * | 2000-05-22 | 2005-10-17 | К'Єзі Фармачеутічі С.П.А. | АЕРОЗОЛЬНА КОМПОЗИЦІЯ, ЩО МІСТИТЬ <font face="Symbol">b</font>2-АДРЕНЕРГІЧНИЙ АГОНІСТ ТРИВАЛОЇ ДІЇ, ДОЗУЮЧИЙ ІНГАЛЯТОР ПІД ТИСКОМ ТА СПОСІБ ЙОГО ЗАПОВНЕННЯ |
| US20060257324A1 (en) * | 2000-05-22 | 2006-11-16 | Chiesi Farmaceutici S.P.A. | Pharmaceutical solution formulations for pressurised metered dose inhalers |
| PL207377B1 (pl) | 2001-03-30 | 2010-12-31 | Jagotec Ag | Medyczny preparat aerozolowy, sposób wytwarzania medycznego preparatu aerozolowego oraz zastosowanie soli kwasów karboksylowych jako środków pomocniczych w tym preparacie |
| US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| EP1321159A1 (en) | 2001-12-21 | 2003-06-25 | CHIESI FARMACEUTICI S.p.A. | Pressurized metered dose inhaler (pMDI) actuators with laser drilled orifices |
| SI3494995T1 (sl) | 2002-03-01 | 2020-08-31 | Chiesi Farmaceutici S.P.A. | Superfina formulacija formoterola |
| MXPA05006383A (es) | 2002-12-16 | 2005-08-29 | Boehringer Ingelheim Pharma | Formulaciones de soluciones de hidrofluorocarburo que contienen tiotropio. |
| AR041873A1 (es) * | 2003-10-30 | 2005-06-01 | Pablo Cassara Srl Lab | Una formulacion farmaceutica en aerosol adecuada para la inhalacion oral o nasal que contienen glucocorticoides en solucion estable al almacenamiento; un metodo para estabilzar formulaciones y uso de un agente estabilizante |
| JP4819699B2 (ja) | 2004-02-06 | 2011-11-24 | メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト | 喘息及びｃｏｐｄの長期間の治療のための抗コリン作用薬及びグルココルチコイドの組合せ剤 |
| ATE399027T1 (de) * | 2004-02-06 | 2008-07-15 | Meda Pharma Gmbh & Co Kg | Neue kombination von anticholinergen und beta mimetika zur behanldung von atemwegserkrankungen |
| GB0410399D0 (en) | 2004-05-10 | 2004-06-16 | Arakis Ltd | The treatment of respiratory disease |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| EP1616567A1 (en) | 2004-07-16 | 2006-01-18 | Boehringer Ingelheim Pharma GmbH & Co.KG | Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts |
| GB0505545D0 (en) | 2005-03-17 | 2005-04-27 | Glaxo Group Ltd | Inhalation devices |
| US20090298802A1 (en) | 2005-03-30 | 2009-12-03 | Sequeira Joel A | Pharmaceutical Compositions |
| GB0523653D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| KR20080032136A (ko) | 2005-08-01 | 2008-04-14 | 아스트라제네카 아베 | 흡입기 밸브 |
| GB0523656D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| GB0523654D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| GB0523655D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| PL1971369T3 (pl) | 2005-12-21 | 2010-01-29 | Meda Pharma Gmbh & Co Kg | Połączenie R,R-glikopirolanu, rolipramu i budesonidu dla potrzeb leczenia chorób zapalnych |
| GB0613161D0 (en) | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
| EP1894568A1 (en) | 2006-08-31 | 2008-03-05 | Novartis AG | Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases |
| AU2008314628B2 (en) | 2007-10-18 | 2014-03-06 | Rose U | Topical glycopyrrolate formulations |
| EP2440196A4 (en) * | 2009-06-09 | 2013-01-02 | Elevation Pharmaceuticals Inc | TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY ADMINISTRATION OF BETA 2 NEBULIZED AGONIST OR A COMBINATION OF BETA 2 NEBULIZED AGONIST AND ANTICHOLINERGIC |
| PE20121467A1 (es) * | 2009-12-23 | 2012-11-07 | Chiesi Farma Spa | Formulacion de aerosol para la enfermedad pulmonar obstructiva cronica |
| ES2467928T3 (es) * | 2009-12-23 | 2014-06-13 | Chiesi Farmaceutici S.P.A. | Formulación en aerosol para EPOC |
| ES2468835T3 (es) * | 2009-12-23 | 2014-06-17 | Chiesi Farmaceutici S.P.A. | Terapia combinada para EPOC |
| JP5914354B2 (ja) * | 2009-12-23 | 2016-05-11 | シエシー ファルマセウティチィ ソシエタ ペル アチオニ | Ｃｏｐｄ用併用療法 |
| SG11201600110RA (en) * | 2013-07-11 | 2016-02-26 | Chiesi Farma Spa | Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation |
| EA033228B1 (ru) * | 2013-12-30 | 2019-09-30 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Находящаяся под давлением стабильная аэрозольная композиция комбинации гликопиррония бромида и формотерола в форме раствора |
| HUE039513T2 (hu) | 2013-12-30 | 2019-01-28 | Chiesi Farm Spa | Glikopirrónium-bromid és formoterol kombinációját tartalmazó nyomás alatti stabil aeroszol oldatkészítmény |
| US9554992B2 (en) * | 2014-06-09 | 2017-01-31 | Chiesi Farmaceutici S.P.A. | Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic |
| US10098837B2 (en) * | 2016-07-28 | 2018-10-16 | Chiesi Farmaceutici S.P.A. | Combination therapy for COPD |
-
2010
- 2010-12-22 JP JP2012545323A patent/JP5914354B2/ja active Active
- 2010-12-22 DK DK10799030.1T patent/DK2515855T6/da active
- 2010-12-22 PE PE2016000787A patent/PE20160853A1/es unknown
- 2010-12-22 CN CN201410289445.6A patent/CN104055765B/zh active Active
- 2010-12-22 CA CA2785321A patent/CA2785321C/en active Active
- 2010-12-22 NZ NZ600790A patent/NZ600790A/en unknown
- 2010-12-22 SI SI201030654T patent/SI2515855T1/sl unknown
- 2010-12-22 ES ES10799030T patent/ES2468840T7/es active Active
- 2010-12-22 PH PH1/2012/501066A patent/PH12012501066A1/en unknown
- 2010-12-22 PE PE2012000865A patent/PE20121396A1/es not_active Application Discontinuation
- 2010-12-22 UA UAA201207626A patent/UA113832C2/uk unknown
- 2010-12-22 BR BR112012015337A patent/BR112012015337B8/pt active IP Right Grant
- 2010-12-22 CN CN201080058048.8A patent/CN102665679B/zh active Active
- 2010-12-22 EA EA201290375A patent/EA021917B1/ru active Protection Beyond IP Right Term
- 2010-12-22 TW TW099145166A patent/TWI495468B/zh active
- 2010-12-22 AU AU2010334859A patent/AU2010334859A1/en not_active Abandoned
- 2010-12-22 PL PL10799030.1T patent/PL2515855T6/pl unknown
- 2010-12-22 EA EA201590179A patent/EA027778B1/ru active Protection Beyond IP Right Term
- 2010-12-22 PT PT107990301T patent/PT2515855E/pt unknown
- 2010-12-22 GE GEAP201012756A patent/GEP20156311B/en unknown
- 2010-12-22 MY MYPI2012002844A patent/MY156949A/en unknown
- 2010-12-22 MX MX2012006878A patent/MX2012006878A/es active IP Right Grant
- 2010-12-22 SG SG2012046157A patent/SG181868A1/en unknown
- 2010-12-22 WO PCT/EP2010/070479 patent/WO2011076843A2/en active Application Filing
- 2010-12-22 EP EP10799030.1A patent/EP2515855B3/en active Active
- 2010-12-22 KR KR1020127015996A patent/KR101757951B1/ko active Active
- 2010-12-22 RS RS20140338A patent/RS53391B2/sr unknown
- 2010-12-22 AR ARP100104922A patent/AR079726A1/es not_active Application Discontinuation
- 2010-12-22 KR KR1020177009412A patent/KR20170040392A/ko not_active Ceased
- 2010-12-23 US US12/977,159 patent/US20110150782A1/en not_active Abandoned
-
2012
- 2012-05-29 TN TNP2012000269A patent/TN2012000269A1/en unknown
- 2012-06-01 CO CO12092198A patent/CO6541628A2/es unknown
- 2012-06-14 MA MA34966A patent/MA33823B1/fr unknown
- 2012-06-21 CL CL2012001705A patent/CL2012001705A1/es unknown
- 2012-06-21 ZA ZA2012/04615A patent/ZA201204615B/en unknown
-
2013
- 2013-02-15 HK HK13101936.0A patent/HK1174566A1/xx unknown
-
2014
- 2014-05-29 CY CY20141100382T patent/CY1115116T1/el unknown
- 2014-06-23 HR HRP20140582TT patent/HRP20140582T4/hr unknown
- 2014-10-23 HK HK14110591A patent/HK1197036A1/xx unknown
-
2015
- 2015-07-29 US US14/812,190 patent/US10159645B2/en active Active
-
2016
- 2016-04-04 JP JP2016075136A patent/JP6283388B2/ja active Active
- 2016-09-27 AU AU2016234895A patent/AU2016234895B2/en active Active
-
2017
- 2017-12-22 CY CY2017047C patent/CY2017047I2/el unknown
- 2017-12-29 FI FIC20170064C patent/FIC20170064I1/fi unknown
- 2017-12-29 FI FIEP10799030.1T patent/FI2515855T6/fi active
-
2018
- 2018-01-05 HU HUS1800001C patent/HUS1800001I1/hu unknown
- 2018-01-10 NO NO2018001C patent/NO2018001I1/no unknown
- 2018-01-10 LU LU00060C patent/LUC00060I2/fr unknown
- 2018-01-11 LT LTPA2018001C patent/LTC2515855I2/lt unknown
- 2018-01-12 NL NL300923C patent/NL300923I2/en unknown
- 2018-04-30 AU AU2018202998A patent/AU2018202998A1/en not_active Abandoned
- 2018-08-01 IL IL260932A patent/IL260932B/en active IP Right Grant
- 2018-10-16 US US16/161,427 patent/US11389401B2/en active Active
-
2019
- 2019-08-02 AR ARP190102199A patent/AR115897A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20121396A1 (es) | Composicion farmaceutica que comprende bromuro de glicopirronio y formoterol | |
| PE20160997A1 (es) | Composicion combinada de bromuro de glicopirronio y formoterol en solucion estable presurizada para aerosol | |
| JP2010132695A5 (es) | ||
| PH12015501964A1 (en) | Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c | |
| PE20091852A1 (es) | Formulacion farmaceutica que comprende un anticuerpo de ox40l | |
| NZ708593A (en) | Novel pyrazole derivative | |
| PE20091672A1 (es) | Nueva dosificacion y formulacion | |
| CO6331425A2 (es) | Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida | |
| PE20160155A1 (es) | Composiciones, metodos y sistemas para el suministro por via respiratoria de tres o mas agentes activos | |
| MX2009004475A (es) | Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma. | |
| PE20070951A1 (es) | Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva | |
| PE20081789A1 (es) | Composicion farmaceutica que contiene aclidino | |
| MY166890A (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| PE20121467A1 (es) | Formulacion de aerosol para la enfermedad pulmonar obstructiva cronica | |
| PE20091392A1 (es) | Composiciones farmaceuticas como agentes antiinflamatorios | |
| MX2012005689A (es) | Analogos de acido araquidonico y metodos para el tratamiento analgesico utilizando los mismos. | |
| AR072805A1 (es) | Composiciones intranasales formas galenicas y metodos de tratamiento. | |
| RU2012125966A (ru) | Комбинированное лечение хронического обструктивного заболевания легких | |
| CO6280574A2 (es) | Metodos para utilizar antagonistas de vasopresina con agentes de quimioterapia con antraciclina para reducir la cardiotoxicidad y/o para mejorar la supervivencia | |
| PE20071231A1 (es) | Formulaciones farmaceuticas de pleconaril | |
| AR100368A1 (es) | Tratamiento de trastornos respiratorios | |
| CO7170176A2 (es) | Nuevo compuesto que tiene la capacidad para inhibir la enzima deshidrogenasa11b-hidroxiesteroide tipo 1(11b-hsd1) o sal farmaceúticamente aceptable del mismo, método para producir el mismo, y composición farmaceútica que contiene el mismo como ingrediente activo | |
| BR112014004879A2 (pt) | uso de inibidor de aromatase para tratamento de hipogonadismo e doenças relacionadas | |
| CO6220945A2 (es) | Uso de una composicion que comprende formoterol y dipropianato de beclometasona para la prevencion y/o tratamiento de una exacerbacion de asma | |
| MX2013001279A (es) | Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal | ||
| AE | Restoration of lapsed or forfeited application | ||
| FC | Refusal |